Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (escape-2), a randomized, double-blind, placebo-controlled trial

  • Neil Singla
  • , David C. Warltier
  • , Sweeta D. Gandhi
  • , Philip D. Lumb
  • , Robert N. Sladen
  • , Solomon Aronson
  • , Mark F. Newman
  • , Howard L. Corwin

Producción científica: Articlerevisión exhaustiva

95 Citas (Scopus)

Resumen

BACKGROUND: Acute postoperative hypertension is a well-known complication of cardiac surgery and is associated with postoperative morbidity. Clevidipine, an ultrashort-acting, third-generation dihydropyridine calcium channel blocker, exerts vascular-selective, arterial-specific vasodilation to decrease arterial blood pressure without negatively impacting cardiac function. In this double-blind, placebo-controlled trial, we examined the efficacy and safety of clevidipine in treating postoperative hypertension in cardiac surgery patients. METHODS: Two hundred six patients undergoing cardiac surgery were randomized preoperatively. Of these, 110 met postrandomization inclusion criteria for the study [systolic blood pressure (SBP) ≥140 mm Hg within 4 h of admission to a postoperative setting, and clinically assessed as needing SBP reduction by ≥15% from baseline]. Patients received an infusion of either clevidipine (0.4-8.0 μg kg min) or 20% lipid emulsion (placebo) for 30 min to a maximum of 1 h unless treatment failure occurred sooner. The primary end point was the incidence of treatment failure, defined as the inability to decrease SBP by ≥15% from baseline, or the discontinuation of study treatment for any reason within the 30-min period after study drug initiation. RESULTS: Clevidipine-treated patients had a significantly lower incidence of treatment failure than placebo patients [8.2% (5 of 61) vs 79.6% (39 of 49), P < 0.0001]. Treatment success was achieved in 91.8% of clevidipine-treated patients. Median time to target SBP with clevidipine was 5.3 min (95% confidence interval, 4-7 min). No clinically significant increase in heart rate from baseline was observed. Adverse event rates were similar for both treatment groups. CONCLUSIONS: Clevidipine is effective and safe in the rapid treatment of acute postoperative hypertension after cardiac surgery.

Idioma originalEnglish
Páginas (desde-hasta)59-67
Número de páginas9
PublicaciónAnesthesia and Analgesia
Volumen107
N.º1
DOI
EstadoPublished - jul 2008

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Huella

Profundice en los temas de investigación de 'Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (escape-2), a randomized, double-blind, placebo-controlled trial'. En conjunto forman una huella única.

Citar esto